Scala, Serena
Basso-Ricci, Luca
Dionisio, Francesca
Pellin, Danilo
Giannelli, Stefania
Salerio, Federica Andrea
Leonardelli, Lorena
Cicalese, Maria Pia
Ferrua, Francesca
Aiuti, Alessandro
Biasco, Luca
Article History
Received: 15 April 2018
Accepted: 7 August 2018
First Online: 1 October 2018
Competing interests
: The WAS gene therapy trial (ExternalRef removed) was originally sponsored by Fondazione Telethon and promoted by San Raffaele Telethon Institute for Gene Therapy (SR-TIGET). GlaxoSmithKline subsequently in-licensed the investigational product (GSK2696275) and became the financial and regulatory sponsor of the study. In April 2018 the license was transferred to Orchard Therapeutics. A.A. is the principal investigator (PI) of the clinical trial. L.B. is a consultant to GlaxoSmithKline for the assessment of safety of the WAS GT. All the other authors declare no competing interests. Readers are welcome to comment on the online version of the paper.